Samar A JasserSummaryAffiliation: Thomas Jefferson University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Light during darkness and cancer: relationships in circadian photoreception and tumor biologySamar A Jasser
Department of Neurology, Light Research Program, Thomas Jefferson University, 1025 Walnut Street, Suite 507, Philadelphia, PA 19107, USA
Cancer Causes Control 17:515-23. 2006..Continued rigorous empirical inquiry into the physiology and clinical implications of these habitual, integrated aspects of life is highly warranted at this time...
Dim light adaptation attenuates acute melatonin suppression in humansSamar A Jasser
Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA
J Biol Rhythms 21:394-404. 2006....
Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude ratsDavid E Blask
Laboratory of Chrono Neuroendocrine Oncology, Bassett Research Institute, The Mary Imogene Bassett Hospital, Cooperstown, New York 13326, USA
Cancer Res 65:11174-84. 2005..These mechanistic studies are the first to provide a rational biological explanation for the increased breast cancer risk in female night shift workers...
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activityDimpy Koul
Department of Neuro Oncology, Box 100, The Brain Tumor Center, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, TX 77030, USA
Oncogene 21:2357-64. 2002..Thus, Y240A and Y315A are involved in the ability of MMAC/PTEN to dephosphorylate PtdIns and regulate tumor cell growth in vitro and in vivo...
Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancerF Christopher Holsinger
Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
Clin Cancer Res 9:3183-9. 2003..4 versus 37.8; P = 0.016). CONCLUSIONS: Combination therapy with paclitaxel and PKI166 prolongs survival in an orthotopic preclinical model of tongue cancer by increasing programmed cell death of oral cancer...
